Document:

<PAGE>

                                                                  Exhibit 10.8
INTERMUNE
PHARMACEUTICALS

October 28, 1999

Timothy P. Lynch
1340 Lombard Street, Apt. 1
San Francisco, CA 94109

Dear Mr. Lynch:

On behalf of InterMune Pharmaceuticals, Inc., I am pleased to offer you the
position of Chief Financial Officer and Vice President of Business Development,
reporting to me.

The terms of your employment will be as follows:

Your starting salary will be $160,000 per year. As a full-time employee of
InterMune Pharmaceuticals, you will be eligible for the Company's standard
benefits package including medical and dental insurance coverage. Your position
is exempt, and you will not be eligible for overtime. You will be entitled to
three weeks paid vacation per year, prorated during 1999. As part of your
sign-on bonus, you will be granted two weeks paid vacation during the remainder
of 1999. In addition, you will receive a $10,000 cash payment 30 days after you
begin employment at InterMune.

Subject to approval of the Board of Directors, on date of hire you will be
granted an option to purchase 180,000 shares of InterMune Pharmaceuticals, Inc.
stock. Your right to exercise 165,000 shares of this option will be subject to a
vesting schedule, such that 165,000 shares of your option will be fully vested
at the end of five years completed employment. The remaining 15,000 shares of
stock will fully vest contingent upon the successful completion of a corporate
partnership for one of the Company's products that is acceptable to our board of
directors. The terms and conditions of this option, including vesting, will be
governed by an agreement that you will be required to sign.

In the event of termination of your employment with the Company other than for
cause, or a significant change in your responsibilities following a change in
control of the company, you will be entitled to receive continuation of salary
and benefits for six months following your termination date. In addition, you
will be entitled to continue all vesting with respect to Company stock during
such six-month period.

As a condition of your employment, you will be required to provide proof of US
citizenship or that you are legally entitled to work in the United States, and
to execute and be bound by the terms of the enclosed Proprietary Information and
Invention
                                                       3294 WEST BAYSHORE ROAD
                                                       PALO ALTO, CA  94303
                                                       PHONE: (650) 493-8333
                                                       FAX: (650) 858-2937
<PAGE>

Agreement. In that regard, please be aware that Company policy prohibits all
employees from bringing to the Company, or using in performance of their
responsibilities at the Company, any confidential information, trade secrets, or
propriety material or processes of any previous employer. Employment with the
Company is at will, is not for any specific term and can be terminated by you or
the Company at any time for any reason with or without cause.

This Offer remains open through noon on Wednesday, November 3, 1999. Upon
acceptance of this offer, the terms described in this letter and in the
Proprietary Information and Invention Agreement shall be the terms of your
employment, superseding any other employment agreements or understandings with
InterMune. Any additions or modifications of these terms must be in writing and
signed by you and an officer of InterMune Pharmaceuticals, Inc. Your anticipated
date of your start of hire is November 1, 1999.

Again, let me indicate how pleased I am to extend this offer, and how much we at
InterMune look forward to working with you. We anticipate that you will find
this an exciting and challenging position in a dynamic and growing company.

Again, let me indicate how pleased we are to extend this offer, and how much we
at InterMune look forward to working with you. We anticipate that you will find
this an exciting and challenging position in a dynamic and growing company.

Please indicate your acceptance by signing and returning the enclosed duplicate
original of this letter to me.

Very truly yours,

/s/ W. Scott Harkonen

W. Scott Harkonen, M.D.
President and CEO
InterMune Pharmaceuticals, Inc.

UNDERSTOOD AND ACCEPTED:

      /s/Timothy P. Lynch                         10/25/99
----------------------------------------------------------
Timothy P. Lynch                                      Date<PAGE>

                                                                  Exhibit 10.9
INTERMUNE
PHARMACEUTICALS

October 22, 1999

Peter Van Vlasselaer, Ph.D.
1065 Hickorynut Court
Sunnyvale, California 94087

Dear Dr. Van Vlasselaer:

On behalf of InterMune Pharmaceuticals, Inc., I am pleased to offer you the
position of Senior Vice President, Technical Operations, reporting to me at our
facility located at 3294 East Bayshore Road in Palo Alto.

The terms of your employment will be as follows:

Your starting salary will be $165,000 per year. As a full-time employee of
InterMune Pharmaceuticals, you will be eligible for the Company's standard
benefits package including medical and dental insurance coverage. Your position
is exempt, and you will not be eligible for overtime. You will be entitled to
three weeks paid vacation per year, prorated during 1999. The Company will
provide you with a one-time sign-on bonus of $10,000 one month following your
first day of employment.

Subject to approval of the Board of Directors, on date of hire you will be
granted an option to purchase 160,000 shares of InterMune Pharmaceuticals, Inc.
stock. Your right to exercise this option will be subject to a vesting schedule,
such that your option will be fully vested at the end of five years completed
employment. The terms and conditions of this option, including vesting, will be
governed by an agreement that you will be required to sign.

As a condition of your employment, you will be required to provide proof of US
citizenship or that you are legally entitled to work in the United States, and
to execute and be bound by the terms of the enclosed Proprietary Information and
Invention Agreement. In that regard, please be aware that Company policy
prohibits all employees from bringing to the Company, or using in performance of
their responsibilities at the Company, any confidential information, trade
secrets, or propriety material or processes of any previous employer. Employment
with the Company is at will, is not for any specific term and can be terminated
by you or the Company at any time for any reason with or without cause.

                                                    3294 WEST BAYSHORE ROAD
                                                    PALO ALTO, CA  94303
                                                    PHONE: (650) 493-8333
                                                    FAX: (650) 858-2937
<PAGE>

Offer of Employment
Peter Van Vlasselaer, Ph.D.
Page 2 of 2

In the event of termination of your employment with the Company other than for
cause, you will be entitled to receive continuation of salary and benefits for
three months following your termination date. In addition, you will be entitled
to continue all vesting with respect to Company stock during such three-month
period.

This offer remains open through noon on Friday, October 29, 1999. Upon
acceptance of this offer, the terms described in this letter and in the
Proprietary Information and Invention Agreement shall be the terms of your
employment, superseding any other employment agreements or understandings with
InterMune. Any additions or modifications of these terms must be in writing and
signed by you and an officer of InterMune Pharmaceuticals, Inc.

Again, let me indicate how pleased I am to extend this offer, and how much we at
InterMune are looking forward to working with you. We anticipate that you will
find this an exciting and challenging position in a dynamic and growing company.

Please indicate your acceptance by signing and returning the enclosed duplicate
original of this letter to me.

Very truly yours,

/s/ W. Scott Harkonen

W. Scott Harkonen, M.D.
President and CEO
InterMune Pharmaceuticals, Inc.

UNDERSTOOD AND ACCEPTED:

       /s/ Peter Van Vlasselaer, Ph.D.             10/26/99
-----------------------------------------------------------
Peter Van Vlasselaer, Ph.D.                        Date<PAGE>

                                                                  Exhibit 10.10

INTERMUNE
PHARMACEUTICALS

Ms. Christine W. Czamiecki
1950 Clay Street, Apt. 204
San Francisco, CA 94109

Dear Christine:

On behalf of InterMune Pharmaceuticals, Inc., we are pleased to offer you the
position of Vice President, Regulatory Affairs, reporting to Scott Harkonen,
Chief Executive Officer and President.

The terms of your employment will be as follows:

Your starting salary will be $175,000 per year. As a full-time employee of
InterMune Pharmaceuticals, you will be eligible for the Company's standard
benefits package including medical and dental insurance coverage. Your position
is exempt, and you will not be eligible for overtime. You will be entitled to
three weeks paid vacation per year.

Subject to approval of the Board of Directors, on date of hire you will be
granted an option to purchase 105,000 shares of InterMune Pharmaceuticals, Inc.
stock at an exercise price of $0.25. Your right to exercise the shares of this
option will be subject to a vesting schedule, such that 105,000 shares of your
option will be fully vested at the end of five years completed employment. The
terms and conditions of this option, including vesting, will be governed by an
agreement that you will be required to sign.

As a condition of your employment, you will be required to provide proof of
US citizenship or that you are legally entitled to work in the United States,
and to execute and be bound by the terms of the enclosed Proprietary
Information and Invention Agreement. In that regard, please be aware that
Company policy prohibits all employees from bringing to the Company, or using
in performance of their responsibilities at the Company, any confidential
information, trade secrets, or propriety material or processes of any
previous employer. Employment with the Company is at will, is not for any
specific term and can be terminated by you or the Company at any time for any
reason with or without cause.

                                                       3294 WEST BAYSHORE ROAD
                                                       PALO ALTO, CA  94303
                                                       PHONE: (650) 493-8333
                                                       FAX: (650) 858-2937
<PAGE>

In the event of termination of your employment with the Company other than for
cause, you will be entitled to receive continuation of salary and benefits for
four months following your termination date. In addition, you will be entitled
to continue all vesting with respect to Company stock during such four-month
period.

This offer remains open through Friday, December 31, 1999. Upon acceptance of
this offer, the terms described in this letter and in the Proprietary
Information and Invention Agreement shall be the terms of your employment,
superseding any other employment agreements or understandings with InterMune.
Any additions or modifications of these terms must be in writing and signed by
you and an officer of InterMune Pharmaceuticals, Inc. Your anticipated date of
hire is Monday, February 1, 2000.

Again, let me indicate how pleased we are to extend this offer, and how much we
at InterMune look forward to working with you. We anticipate that you will find
this an exciting and challenging position in a dynamic and growing company.

Please indicate your acceptance by signing and returning the enclosed duplicate
original of this letter to me.

Very truly yours,

/s/ W. Scott Harkonen

W. Scott Harkonen, M.D.
President and CEO
InterMune Pharmaceuticals, Inc.

UNDERSTOOD AND ACCEPTED:

         /s/ Christine W. Czarniecki                           23, December 1999
--------------------------------------------------------------
         Christine W. Czarniecki                               Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}]]